Yuri Martina

Dr. Martina is a Medical Doctor with a PhD in Genetics and Molecular Biology, an MBA and a Master’s in Project Management. He has more than 20 years’ experience in clinical development working with key regulatory, industry and government stakeholders including the EMA, the FDA and the PMDA in Japan. Dr. Martina has experience of the US, Middle East and Asia and has contributed to more than ten new drug product submissions to the EMA and/or the FDA. Previously, Dr. Martina was SVP Development and deputy CMO at Grünenthal Group where he was a key member of the Global R&D Leadership and Commercial Leadership Teams and has been responsible for advancing the R&D pipeline, including phase 2 and 3 assets and several earlier programs. Dr. Martina has also been involved in business development and in the completion of the acquisition of Mestex AG. From 2014 to 2017, Dr. Martina was Vice President Development and Clinical Operations in Shionogi Europe, where he was a key contributor to the approval of Mulpeo and Cefiderocol and has also had several roles in mid-size and large pharmaceutical companies and at academic institutions.